Synthesis of Gd-DTPA Carborane-Containing Compound and Its Immobilization on Iron Oxide Nanoparticles for Potential Application in Neutron Capture Therapy
Authors:
- Ilya V. KorolkovIlya V. Korolkov
- Alexander ZaboronokAlexander Zaboronok
- Kairat A. IzbasarKIKairat A. Izbasar
- Zhangali A. BekbolZBZhangali A. Bekbol
- Lana I. LissovskayaLLLana I. Lissovskaya
- Alexandr V. ZibertAZAlexandr V. Zibert
- Rafael I. ShakirzyanovRafael I. Shakirzyanov
- Luiza N. KorganbayevaLKLuiza N. Korganbayeva
- Haolan YangHaolan Yang
- Eiichi IshikawaEIEiichi Ishikawa
- Maxim V. ZdorovetsMZMaxim V. Zdorovets
Open Access
- 12 June 2024
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (6) , 797
Abstract
Cancer is one of the leading causes of global mortality, and its incidence is increasing annually. Neutron capture therapy (NCT) is a unique anticancer modality capable of selectively eliminating tumor cells within normal tissues. The development of accelerator-based, clinically mountable neutron sources has stimulated a worldwide search for new, more effective compounds for NCT. We synthesized magnetic iron oxide nanoparticles (NPs) that concurrently incorporate boron and gadolinium, potentially enhancing the effectiveness of NCT. These magnetic nanoparticles underwent sequential modifications through silane polycondensation and allylamine graft polymerization, enabling the creation of functional amino groups on their surface. Characterization was performed using Fourier-transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), energy dispersive X-ray (EDX), dynamic light scattering (DLS), thermal gravimetric analysis (TGA), and transmission electron microscopy (TEM). ICP-AES measurements indicated that boron (B) content in the NPs reached 3.56 ppm/mg, while gadolinium (Gd) averaged 0.26 ppm/mg. Gadolinium desorption was observed within 4 h, with a peak rate of 61.74%. The biocompatibility of the NPs was confirmed through their relatively low cytotoxicity and sufficient cellular tolerability. Using NPs at non-toxic concentrations, we obtained B accumulation of up to 5.724 × 1010 atoms per cell, sufficient for successful NCT. Although limited by its content in the NP composition, the Gd amount may also contribute to NCT along with its diagnostic properties. Further development of the NPs is ongoing, focusing on increasing the boron and gadolinium content and creating active tumor targeting.Keywords
Funding Information
- Ministry of Energy of the Republic of Kazakhstan (BR20081011, 23K06738)
- Japanese Ministry of Education, Culture, Sports, Science, and Technology (BR20081011, 23K06738)
This publication has 47 references indexed in Scilit:
- Hadron therapy in radiation oncology and why BNCT is a paradigm shiftHealth and Technology, 2024
- Biocompatible Iron–Boron Nanoparticles Designed for Neutron Capture Therapy Guided by Magnetic Resonance ImagingAdvanced Healthcare Materials, 2020
- Boron neutron capture therapy: Current status and future perspectivesCancer Communications, 2020
- Critical review, with an optimistic outlook, on Boron Neutron Capture Therapy (BNCT)Applied Radiation and Isotopes, 2014
- Boron and Gadolinium Neutron Capture Therapy2013
- Neutron Capture Therapy2012
- The Iron Oxides2003
- Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician’s point of viewJournal of Neuro-Oncology, 2003
- A critical assessment of boron target compounds for boron neutron capture therapyJournal of Neuro-Oncology, 2003
- Comparison of Radiation Effects of Gadolinium and Boron Neutron Capture ReactionsStrahlentherapie und Onkologie, 2000